Comparative efficacy and safety of sorafenib in elderly versus non-elderly patients with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction.
Sukeshi Patel Arora(The University of Texas MD Anderson Cancer Center), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Joel Michalek(The University of Texas at San Antonio Health Science Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center), Norma S. Ketchum(The University of Texas at San Antonio Health Science Center)
Cited by 2
Related Papers
Targeting HSP90 for cancer therapy
|British Journal of Cancer|2009|320
Combined autophagy and HDAC inhibition
|Autophagy|2014|292
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
|Blood|2010|278
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
|EBioMedicine|2023|275
Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer
|European Urology|2018|224